Healthcare / Drug Manufacturers - Specialty & GenericThailand
$36.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $2.1B · quality 81.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$31.4B
P/E
15.3x
↓EV/EBITDA
10.1x
↓ROE
18.7%
↑Gross Margin
52.2%
↑Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-3.4%
FCF CAGR
+7.7%
FCF margin
14.9%
FCF / Net income
1.10x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $14.15B · net income $1.91B · FCF $2.10B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $14.15B | $14.15B | $15.34B | $15.68B | $15.69B |
| Net Income | $1.91B | $1.91B | $2.01B | $1.99B | $2.24B |
| EBITDA | $2.74B | $2.74B | $2.67B | $2.58B | $2.90B |
| EPS | 2.19 | 2.19 | 2.31 | 2.29 | 2.57 |
| Gross Margin | 52.2% | 52.2% | 50.5% | 45.2% | 44.9% |
| Operating Margin | 20.5% | 20.5% | 22.0% | 18.5% | 17.1% |
| Net Margin | 13.5% | 13.5% | 13.1% | 12.7% | 14.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.07 | 0.07 | 0.05 | 0.03 | 0.05 |
| Current Ratio | 2.23 | 2.23 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $2.10B | $2.10B | $2.14B | $1.63B | $1.68B |
| Returns | |||||
| ROE | 18.7% | 18.7% | 20.4% | 21.4% | 25.5% |
| Valuation | |||||
| P/E | 15.25 | 15.25 | 14.15 | 17.14 | 19.30 |
| EV/EBITDA | 10.14 | 10.14 | 9.54 | 12.46 | 14.23 |
| P/B | 3.07 | 3.07 | 2.88 | 3.68 | 4.93 |
| Growth & Yield | |||||
| Revenue Growth | -7.8% | -7.8% | -2.1% | -0.0% | — |
| EPS Growth | -5.2% | -5.2% | 0.9% | -10.9% | — |
| Dividend Yield | 4.7% | 4.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
13.4%
EPS terminal req.
$3.19
Spread vs growth
-18.6%
5Y implied EPS CAGR
12.0%
EPS terminal req.
$3.87
Spread vs growth
-17.2%
10Y implied EPS CAGR
11.0%
EPS terminal req.
$6.22
Spread vs growth
-16.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+13.5%
Start / end P/E
13.5x → 15.4x
EPS bridge
2.31 → 2.19
Residual
-0.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.